Lymphoma Clinical Trials in Massachusetts

Showing 541-548 of 548 trials

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471

The treatment being investigated is a patient- and tumor-specific therapy known as a personalized active immunotherapy. Personalized active immunotherapy is an attempt to use a person's own immune system to combat disease. Sargramostim (a.k.a. GM-CSF) is given together with the personalized active immunotherapy because it may increase the immune system's response and, therefore, aid in the effect of the personalized active immunotherapy. This approach has previously been studied in patients with follicular Non-Hodgkin's lymphoma and other B-cell malignancies. Encouraging efficacy results and a favorable safety profile have been seen to date in these studies.

Non-Hodgkin's Lymphoma

Genitope CorporationStarted May 2007

Los Angeles, California, United States • Denver, Colorado, United States • Indianapolis, Indiana, United States +6 more locations

TERMINATEDPhase 126 miles

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313

For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507. For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.

LymphomaLeukemiaCancer

MedImmune LLC80 participantsStarted Feb 2005

Los Angeles, California, United States • New Haven, Connecticut, United States • Washington D.C., District of Columbia, United States +8 more locations

Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma Trials in Other Cities

Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Other Conditions in Massachusetts